ProSci

EndoG Antibody

Product Code:
 
PSI-3035
Product Group:
 
Primary Antibodies
Supplier:
 
ProSci
Host Type:
 
Rabbit
Antibody Isotype:
 
IgG
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)
1 / 14
<strong>Figure 1 Western Blot Validation in Mouse 3T3 (M) and Human HepG2 (H) Cell Lysates</strong><br> Loading: 15 μg of lysates per lane. Antibodies: EndoG 3035 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
2 / 14
<strong>Figure 2 Western Blot Validation in Human A431 Cell Lysate with the presence (A) or absence (B and C) of blocking peptide</strong><br> Loading: 15 μg of lysates per lane. Antibodies: EndoG 3035 (A: 0.5 μg/mL, B: 0.5 μg/mL, C: 1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
3 / 14
<strong>Figure 3 Western Blot Validation with Recombinant Protein</strong><br> Loading: 30 ng of human EndoG recombinant protein per lane. Antibodies: EndoG 3035, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 μg/mL Lane 2: 1 μg/mL Lane 3: 2 μg/mL
4 / 14
<strong>Figure 4 Immunofluorescence Validation of EndoG in Human Pancreas Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human pancreas tissue labeling EndoG with 3035 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
5 / 14
<strong>Figure 5 Immunohistochemistry Validation of EndoG in Human Pancreas Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-EndoG antibody (3035) at 15 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
6 / 14
<strong>Figure 6 Immunohistochemistry Validation of EndoG in Human Pancreas Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-EndoG antibody (3035) at 2.5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
7 / 14
<strong>Figure 7 Localization Validation of EndoG by Purified p53 in Human Colorectal Cancer (HCT116) WT Cells (Wolff et al., 2008) </strong><br> Immunoblot analysis of subcellular fraction enriched with supernatant (S) was used to determine EndoG protein levels with increasing amounts of p53 (10, 20, 40, 100nM) in HCT116 WT cells. The release of EndoG from mitochondria induced by p53 is detected by anti-EndoG antibodies.
8 / 14
<strong>Figure 8 Localization Validation of EndoG in LHON cybrids (Zanna et al., 2005) </strong><br> Immunoblots of subcellular fractions enriched for (A) cytosol and (B) mitochondria were used to determine EndoG protein levels with anti-EndoG antibodies in LHON cybrids. The release of EndoG from mitochondria into the cytosol of 3460/ND1 mutant is observed after 24hr. Control (HGA) was unaffected.
9 / 14
<strong>Figure 9 Tissue Specificity of EndoG in Rat Organs ( Siu et al., 2007) </strong><br> WB analysis with anti-EndoG antibodies was performed for (B) EndoG in different organs of rats. EndoG was expressed very high in the heart and the liver of rats.
10 / 14
<strong>Figure 10 Immunohistochemistry Validation of EndoG translocation in Rat Spinal Cord Tissue (Yu et al., 2006) </strong><br> Protein analysis for EndoG translocation by immunohistochemistry with anti-EndoG antibodies in Rat spinal cord tissue. The staining showed that EndoG was expressed in the nuclei of SCI rats (1d) as compared to the perikarya (cytoplasm) in WT.
11 / 14
<strong>Figure 11 Translocation of EndoG by α-chaconine (CHA) and gallic acid (GA) in Human Prostate Cancer Cells (Reddivari et al., 2010) </strong><br> Lymph-node carcinoma of the prostate (LNCaP) or prostate cancer-3 (PC-3) cells were treated with CHA (2.5 μg/ml) or GA (15 μg/ml) for 24hr. EndoG expression detected by anti-EndoG antibodies was increased significantly in nuclear fraction after CHA or GA treatments while this effect was not observed in the solvent control (C).
12 / 14
<strong>Figure 12 Translocation of EndoG by Cisplatin in Human HN4 cells (Kim et al., 2008) </strong><br> Head and Neck Squamous Cell Carcinoma (HNSCC), HN4 cells, from the patients were treated with 40 uM cisplatin. An increased expression of EndoG was induced in the nuclear fraction by cisplatin treatment, which was not observed in the mitochondria.
13 / 14
<strong>Figure 13 KD Validation of EndoG in Human small cell lung carcinoma Ms-1/Bcl-xL Cells (Sasazawa et al., 2009) </strong><br> Western blot analysis with anti-EndoG antibodies was performed for EndoG in Ms-1/Bcl-xL cells transfected with EndoG siRNA or control siRNA. EndoG expression was downregulated after EndoG siRNA knockdown.
14 / 14
<strong>Figure 14 KD Validation of EndoG in Human MCF7 Cells (Schneiders et al., 2009) </strong><br> Western blot analysis with anti-EndoG antibodies was performed for EndoG in MCF7 cells transfected with EndoG siRNA or nonsense siRNA. EndoG expression was downregulated and cell apoptosis rate was remarkably decreased after EndoG siRNA knockdown.
❮❯

<strong>Figure 1 Western Blot Validation in Mouse 3T3 (M) and Human HepG2 (H) Cell Lysates</strong><br> Loading: 15 μg of lysates per lane. Antibodies: EndoG 3035 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 2 Western Blot Validation in Human A431 Cell Lysate with the presence (A) or absence (B and C) of blocking peptide</strong><br> Loading: 15 μg of lysates per lane. Antibodies: EndoG 3035 (A: 0.5 μg/mL, B: 0.5 μg/mL, C: 1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 3 Western Blot Validation with Recombinant Protein</strong><br> Loading: 30 ng of human EndoG recombinant protein per lane. Antibodies: EndoG 3035, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.5 μg/mL Lane 2: 1 μg/mL Lane 3: 2 μg/mL
<strong>Figure 4 Immunofluorescence Validation of EndoG in Human Pancreas Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human pancreas tissue labeling EndoG with 3035 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
<strong>Figure 5 Immunohistochemistry Validation of EndoG in Human Pancreas Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-EndoG antibody (3035) at 15 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
<strong>Figure 6 Immunohistochemistry Validation of EndoG in Human Pancreas Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-EndoG antibody (3035) at 2.5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
<strong>Figure 7 Localization Validation of EndoG by Purified p53 in Human Colorectal Cancer (HCT116) WT Cells (Wolff et al., 2008) </strong><br> Immunoblot analysis of subcellular fraction enriched with supernatant (S) was used to determine EndoG protein levels with increasing amounts of p53 (10, 20, 40, 100nM) in HCT116 WT cells. The release of EndoG from mitochondria induced by p53 is detected by anti-EndoG antibodies.
<strong>Figure 8 Localization Validation of EndoG in LHON cybrids (Zanna et al., 2005) </strong><br> Immunoblots of subcellular fractions enriched for (A) cytosol and (B) mitochondria were used to determine EndoG protein levels with anti-EndoG antibodies in LHON cybrids. The release of EndoG from mitochondria into the cytosol of 3460/ND1 mutant is observed after 24hr. Control (HGA) was unaffected.
<strong>Figure 9 Tissue Specificity of EndoG in Rat Organs ( Siu et al., 2007) </strong><br> WB analysis with anti-EndoG antibodies was performed for (B) EndoG in different organs of rats. EndoG was expressed very high in the heart and the liver of rats.
<strong>Figure 10 Immunohistochemistry Validation of EndoG translocation in Rat Spinal Cord Tissue (Yu et al., 2006) </strong><br> Protein analysis for EndoG translocation by immunohistochemistry with anti-EndoG antibodies in Rat spinal cord tissue. The staining showed that EndoG was expressed in the nuclei of SCI rats (1d) as compared to the perikarya (cytoplasm) in WT.
<strong>Figure 11 Translocation of EndoG by α-chaconine (CHA) and gallic acid (GA) in Human Prostate Cancer Cells (Reddivari et al., 2010) </strong><br> Lymph-node carcinoma of the prostate (LNCaP) or prostate cancer-3 (PC-3) cells were treated with CHA (2.5 μg/ml) or GA (15 μg/ml) for 24hr. EndoG expression detected by anti-EndoG antibodies was increased significantly in nuclear fraction after CHA or GA treatments while this effect was not observed in the solvent control (C).
<strong>Figure 12 Translocation of EndoG by Cisplatin in Human HN4 cells (Kim et al., 2008) </strong><br> Head and Neck Squamous Cell Carcinoma (HNSCC), HN4 cells, from the patients were treated with 40 uM cisplatin. An increased expression of EndoG was induced in the nuclear fraction by cisplatin treatment, which was not observed in the mitochondria.
<strong>Figure 13 KD Validation of EndoG in Human small cell lung carcinoma Ms-1/Bcl-xL Cells (Sasazawa et al., 2009) </strong><br> Western blot analysis with anti-EndoG antibodies was performed for EndoG in Ms-1/Bcl-xL cells transfected with EndoG siRNA or control siRNA. EndoG expression was downregulated after EndoG siRNA knockdown.
<strong>Figure 14 KD Validation of EndoG in Human MCF7 Cells (Schneiders et al., 2009) </strong><br> Western blot analysis with anti-EndoG antibodies was performed for EndoG in MCF7 cells transfected with EndoG siRNA or nonsense siRNA. EndoG expression was downregulated and cell apoptosis rate was remarkably decreased after EndoG siRNA knockdown.

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-3035-0.02mg0.02mg£150.00
Quantity:
PSI-3035-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Related Products
  • Show All

Further Information

Additional Names:
EndoG Antibody: Endonuclease G, mitochondrial, Endo G
Application Note:
WB: 0.5-2 μg/mL; IF: 20 μg/mL; IHC: 2.5-15 μg/mL.

Antibody validated: Western Blot in human and mouse samples; Immunofluorescence and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
EndoG Antibody: The fragmentation of nuclear DNA is a hallmark of apoptotic cell death. The activities of caspase and nuclease are involved in the DNA fragmentation. Caspase-activated deoxyribonuclease (CAD), also termed DNA fragmentation factor (DFF40), is one such nuclease, and is capable of inducing DNA fragmentation and chromatin condensation after cleavage by caspase-3 of its inhibitor ICAD/DFF45. Caspase and CAD independent DNA fragmentation also exists. Recent studies demonstrated that another nuclease, endonuclease G (endoG), is specifically activated by apoptotic stimuli and is able to induce nucleosomal fragmentation of DNA independently of caspase and DFF/CAD. EndoG is a mitochondrion-specific nuclease that translocates to the nucleus and cleaves chromatin DNA during apoptosis. The homologue of mammalian EndoG is the first mitochondrial protein identified to be involved in apoptosis in C. elegans. EndooG also cleaves DNA in vitro.
Background References:
  • Li et al. Nature 2001;412(6842):95-9.
  • Parrish et al. Nature 2001;412(6842):90-4.
  • Hengartner. Nature. 2001;412(6842):27, 29.
  • Widlak et al. J Biol Chem. 2001;276(51):48404-9.
Buffer:
EndoG Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Anti-EndoG antibody (3035) was raised against a peptide corresponding to 15 amino acids near the amino terminus of human ENDOG.

The immunogen is located within amino acids 40-90 of EndoG.
ISOFORMS:
Human EndoG has only one isoform (297aa, 33kD). Mouse EndoG has one isoform (294aa, 32kD) and Rat EndoG also has one isoform (294aa, 32kD). 3035 can detect human, mouse and rat isoform.
NCBI Gene ID #:
2021
NCBI Official Name:
endonuclease G
NCBI Official Symbol:
ENDOG
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 33kD

Observed: 33kD
Protein Accession #:
NP_004426
Protein GI Number:
53759134
Purification:
EndoG Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis,Cancer
Swissprot #:
Q14249
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:

KD validation (Figure 13, 14): Anti-EndoG antibody (3035) specificity was further verified by EndoG specific knockdown. EndoG signal in human cancer cell lines transfected with EndoG siRNAs was disrupted in comparison with that in cells transfected with control siRNAs.

Localization validation (Figure 7, 8, 10, 11): EndoG translocation was observed in different cell lines and tissues after treatment. From mitochondria to cytoplasm: figure 7 and figure 8. From cytosol to nucleus: figure 10 and figure 11.

References

  1. Wolff et al. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008;18(7):733-44. PMID: 18504456
  2. Zanna et al. Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and Endonuclease G. Apoptosis. 2005;10(5):997-1007.PMID: 16151635
  3. Siu et al. Response of caspase-independent apoptotic factors to high salt diet-induced heart failure. J Mol Cell Cardiol. 2007;42(3):678-86.PMID: 17292393
  4. Yu et al. Overexpression of SOD1 in transgenic rats attenuates nuclear translocation of endonuclease G and apoptosis after spinal cord injury. J Neurotrauma. 2006;23(5):595-603. PMID: 16689664. PMID: 16689664
  5. Reddivari et al. The bioactive compounds alpha-chaconine and gallic acid in potato extracts decrease survival and induce apoptosis in LNCaP and PC3 prostate cancer cells. Nutr Cancer. 2010;62(5):601-10. PMID: 20574921
  6. Kim et al. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer. 2008;122(3):672-80. PMID: 17955488
  7. Sasazawa et al. Vacuolar H+-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway. Cancer Sci. 2009;100(8):1460-7.PMID: 19459857
  8. Schneiders et al. BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells. Mol Cancer Ther. 2009;8(10):2914-25. PMID: 19808980
  9. Liu et al. Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol. 2006;126(10):2247-56. PMID: 16728972
  10. Cozzolino et al. Apaf1 mediates apoptosis and mitochondrial damage induced by mutant human SOD1s typical of familial amyotrophic lateral sclerosis. Neurobiol Dis. 2006;21(1):69-79.PMID: 16046141
  11. Ory et al. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007;71(1):333-43. PMID: 17050806
  12. Du et al. Resveratrol prevents protein nitration and release of endonucleases from mitochondria during acetaminophen hepatotoxicity. Food Chem Toxicol. 2015;81:62-70. PMID: 25865938
  13. Gozar et al. Dz13, a DNAzyme targeting c-jun, induces off-target cytotoxicity in endothelial cells with features of nonapoptotic programmed cell death. Oligonucleotides. 2008;18(3):257-68. PMID: 18699742
  14. Lartigue et al. Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol Biol Cell. 2009;20(23):4871-84. PMID: 19793916
  15. Boyle et al. Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy. Exp Gerontol. 2011;46(7):549-59. PMID: 21377520